Key Takeaways
- • U.S. biopharma companies raised $37.2 billion since 2025 through Q3 2026, about 68% of the $54.5 billion total global biopharma venture funding across 959 rounds, according to BioSpace citing a J.P. Morgan October biopharma report.
- • The San Francisco Bay Area ($12.8 billion) and Boston ($10.2 billion) together captured roughly 62% of all U.S. biopharma funding over the past seven quarters.
- • Europe raised $9.2 billion, just under 17% of global capital, with the U.K. leading at $3.1 billion across 58 rounds.
- • J.P. Morgan projects 2026 full-year biopharma funding of about $33 billion, surpassing the 2025 total of $30.5 billion.
- • Capital deployment in Q3 2026 was concentrated: five of 32 rounds accounted for half of the $1.1 billion raised in the quarter.
Summary
U.S. biopharma companies have raised $37.2 billion in venture capital since the start of 2025 through the third quarter of 2026, representing about 68% of the $54.5 billion raised worldwide across 959 rounds, according to BioSpace, which cites an October biopharma report from J.P. Morgan.
Capital remains highly concentrated geographically. The San Francisco Bay Area and Boston are the two leading U.S. hubs, raising $12.8 billion and $10.2 billion respectively over the period. Together they gathered about 62% of all U.S. biopharma funding over the past seven quarters, which J.P. Morgan describes as "underscoring the continued concentration of capital in established life-sciences ecosystems." San Diego, Philadelphia and the Research Triangle in North Carolina collectively raised $5.2 billion over the same period.
Outside the U.S., European biopharma companies raised $9.2 billion from 2025 through Q3 2026, just under 17% of total capital deployed. The U.K. led the region with $3.1 billion across 58 rounds, followed by Switzerland at $1.8 billion, France at $851 million and Germany at $832 million.
Deal flow in the most recent quarter was concentrated in fewer, larger rounds. Of the $1.1 billion deployed in Q3 2026, half came from just five of the 32 rounds. J.P. Morgan projects full-year 2026 biopharma funding of about $33 billion, above the $30.5 billion raised in 2025.
While financing exit activity remained strong through the third quarter, public-market performance over the same period was muted, with most of the U.S. biotech-specific index's yearly gains driven by the first half of 2026.
Capital remains highly concentrated geographically. The San Francisco Bay Area and Boston are the two leading U.S. hubs, raising $12.8 billion and $10.2 billion respectively over the period. Together they gathered about 62% of all U.S. biopharma funding over the past seven quarters, which J.P. Morgan describes as "underscoring the continued concentration of capital in established life-sciences ecosystems." San Diego, Philadelphia and the Research Triangle in North Carolina collectively raised $5.2 billion over the same period.
Outside the U.S., European biopharma companies raised $9.2 billion from 2025 through Q3 2026, just under 17% of total capital deployed. The U.K. led the region with $3.1 billion across 58 rounds, followed by Switzerland at $1.8 billion, France at $851 million and Germany at $832 million.
Deal flow in the most recent quarter was concentrated in fewer, larger rounds. Of the $1.1 billion deployed in Q3 2026, half came from just five of the 32 rounds. J.P. Morgan projects full-year 2026 biopharma funding of about $33 billion, above the $30.5 billion raised in 2025.
While financing exit activity remained strong through the third quarter, public-market performance over the same period was muted, with most of the U.S. biotech-specific index's yearly gains driven by the first half of 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.